Patent · US Expired

Thiazolidinedione derivative and its use as antidiabetic

US6815457B1 · kind B1 · utility

1Cited by
7References
41Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 15, 2002
Grant dateNov 9, 2004
Priority date
Expiry dateMay 15, 2022

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P13/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterized in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and 669 cm−1; and/or (ii) provides a Raman spectrum containing peaks at 1581, 768, 670, 271 and 226 cm−1; and/or (iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peaks substantially as set out in Table II; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.